查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1462644

到 2030 年免疫肿瘤检测市场预测：按产品、适应症、技术、应用和地区进行的全球分析

Immuno Oncology Assay Market Forecasts to 2030 - Global Analysis By Product, Indication, Technology, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球免疫肿瘤检测市场规模为 50.4 亿美元，预计在预测期内复合年增长率为 12.8%，到 2030 年将达到 117.1 亿美元。

免疫肿瘤学检测市场是指医疗保健行业内的一个部门，专注于利用人体免疫系统支持癌症研究和治疗的检测方法的开发和商业化。这些检测方法在药物开发中发挥重要作用，能够评估新型免疫肿瘤治疗方法，帮助研究人员识别有前景的候选药物并评估其疗效和安全性。

根据 ECIS 的数据，2040 年欧洲癌症患者人数预计将达到 336 万人，而 2025 年将达到 294 万人。

人们对免疫疗法的兴趣日益浓厚

免疫疗法已成为一种有前途的癌症治疗方法，它利用人体的免疫系统有效对抗肿瘤。传统的癌症治疗经常遇到抗药性，并可能产生严重的副作用，因此免疫疗法很有吸引力，因为它的副作用较少，并且有望产生有针对性的持久反应。免疫肿瘤学检测对于免疫疗法药物的开发和评估至关重要，使研究人员和临床医生能够评估其疗效、安全性和作用机制。

开发成本高

免疫肿瘤学检测法的研发过程包括广泛的验证研究、检测法通讯协定优化和临床验证研究，以确保准确性、重现性和法律规章。此类活动需要大量的财务投资，包括设备、试剂、人员和监管备案。对于资源有限的小型企业来说，高昂的初始成本和漫长的开发时间可能会阻碍它们进入市场并与较大的现有企业进行有效竞争。

技术进步

多重检测、次世代定序(NGS) 和高通量筛检等技术创新使研究人员能够以更高的效率和精度同时分析多个参数，从而彻底改变了免疫肿瘤学领域。多重检测可测量单一样本中的多种分析物，从而全面了解免疫系统与癌细胞之间复杂的相互作用。 NGS 技术为基因组和转录组分析提供了前所未有的机会，有助于识别新型生物标记和治疗标靶。

来自替代技术的竞争

液态切片和诊断成像方法等替代技术具有非侵入性、即时监测和全面分子分析等独特优势。这些替代技术有可能为癌症进展、治疗效果和患者结果提供有价值的见解，并且在许多情况下补充甚至超越免疫肿瘤学测试的能力。因此，研究人员和临床医生可能会选择这些替代方法，特别是在免疫肿瘤学检测受到样本可用性、检测复杂性或成本限制的情况下。

COVID-19 的影响：

最初，疫情爆发扰乱了供应链、实验室业务和临床试验，导致检测开发、验证和商业化延迟。对非必要医疗程序和实验室活动的限制也阻碍了免疫肿瘤学研究的实施以及检测技术在临床实践中的采用。此外，医疗保健资源和资金被用于对抗 COVID-19，从而转移了对免疫肿瘤学研究和开发的注意力和投资。然而，随着大流行的进展，免疫学和感染疾病研究的重要性被认识，可能引发对免疫肿瘤学检测的兴趣和投资。

预计消耗品领域在预测期内将是最大的

在预测期内，消耗品领域占据了市场的最大份额，因为它在支持免疫肿瘤检测的操作和扩充性发挥着至关重要的作用。在癌症发生率上升和免疫疗法普及的推动下，对免疫肿瘤检测的需求持续增长，对耗材的需求也相应增长。此外，检测开发的创新通常依赖于旨在提高检测灵敏度、特异性和通量的专用耗材。这创造了免疫肿瘤检测市场对耗材的持续需求。

流式细胞技术领域预计在预测期内复合年增长率最高

由于流式细胞技术仪在分析免疫细胞群及其在肿瘤微环境中的相互作用方面的多功能性和精确性，预计在预测期内将出现最高的复合年增长率。在单细胞层面同时测量多个参数的能力为了解免疫细胞表型、活化状态和功能反应提供了宝贵的见解。此外，流式细胞技术可以评估免疫查核点表达和细胞激素的产生，有助于评估免疫治疗效果和患者分层。

占比最高的地区

在估计期间，亚太地区占据最大份额。随着人口快速增长、人口老化和生活方式的改变，亚太国家的癌症发病率和死亡率正在迅速上升。都市化、烟草消费、污染和饮食习惯等因素导致该地区癌症发生率增加。因此，医疗基础设施的改善、诊断服务的获取以及对癌症筛检计划的认识的提高正在导致癌症患者的早期发现和诊断。

复合年增长率最高的地区：

预计欧洲地区在预测期内将实现盈利成长。欧洲药品管理局 (EMA) 和欧盟委员会等欧洲监管机构建立的严格法规结构确保了临床研究和患者治疗中使用的免疫肿瘤检测的安全性、有效性和品质。欧洲法规环境强调透明度、基于证据的决策和道德考虑，这有助于在相关人员之间建立对免疫肿瘤学检测的信任和信心。因此，监管合规性将透过促进及时进入市场、促进创新以及加速在整个欧洲采用精准医学和个人化癌症治疗的免疫肿瘤学测试来推动市场成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次研究资料
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球免疫肿瘤检测市场：依产品

  • 软体
  • 消耗品
  • 装置
  • 其他产品

第六章全球免疫肿瘤检测市场：依适应症分类

  • 膀胱癌
  • 黑色素瘤癌症
  • 肺癌
  • 大肠直肠癌
  • 乳癌
  • 淋巴瘤
  • 其他适应症

第七章全球免疫肿瘤检测市场：依技术分类

  • 聚合酵素链锁反应(PCR)
  • 免疫学测试
  • 流式细胞技术
  • 次世代定序（NGS）
  • 原位杂交
  • 其他技术

第八章全球免疫肿瘤检测市场：依应用分类

  • 临床诊断
  • 研究用途
  • 其他用途

第九章全球免疫肿瘤检测市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Agilent Technologies, Inc
  • Bio-Rad Laboratories, Inc
  • Charles River Laboratories, Inc
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc
  • HTG Molecular Diagnostics, Inc
  • llumina, Inc
  • NanoString Technologies, Inc
  • Novartis International AG
  • Perkinelmer, Inc
  • Qiagen Nv
  • Sartorius AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc
Product Code: SMRC25695

According to Stratistics MRC, the Global Immuno Oncology Assay Market is accounted for $5.04 billion in 2023 and is expected to reach $11.71 billion by 2030 growing at a CAGR of 12.8% during the forecast period. The Immuno Oncology Assay Market refers to the sector within the healthcare industry focused on developing and commercializing assays that aid in the study and treatment of cancer by harnessing the body's immune system. These assays play a pivotal role in drug development by enabling the evaluation of novel immuno-oncology therapies, helping researchers identify promising candidates and assess their efficacy and safety profiles.

According to the ECIS, the European cancer burden is expected to reach 3.36 million new cases by 2040, compared to 2.94 million patients in 2025.

Market Dynamics:

Driver:

Growing interest in immunotherapy

Immunotherapy has emerged as a promising approach for cancer treatment, leveraging the body's immune system to combat tumors effectively. As traditional cancer treatments often encounter resistance and can have severe side effects, the appeal of immunotherapy lies in its potential for targeted and durable responses with fewer adverse effects. Immuno-oncology assays are integral to the development and evaluation of immunotherapeutic agents, allowing researchers and clinicians to assess their efficacy, safety, and mechanism of action.

Restraint:

High development costs

The research and development (R&D) process for immuno-oncology assays involves extensive validation studies, optimization of assay protocols, and clinical validation trials to ensure accuracy, reproducibility, and regulatory compliance. These activities require substantial financial investment, including expenditures on equipment, reagents, personnel, and regulatory submissions. For smaller companies with limited resources, the high upfront costs and long development timelines can be prohibitive, preventing them from entering the market or competing effectively with larger established players.

Opportunity:

Technological advancements

Innovations such as multiplex assays, next-generation sequencing (NGS), and high-throughput screening are revolutionizing the field of immuno-oncology by enabling researchers to analyze multiple parameters simultaneously with greater efficiency and precision. Multiplex assays allow the measurement of multiple analytes in a single sample, providing comprehensive insights into the complex interactions between the immune system and cancer cells. NGS technologies offer unprecedented opportunities for genomic and transcriptomic profiling, facilitating the identification of novel biomarkers and therapeutic targets.

Threat:

Competition from alternative technologies

Alternative technologies such as liquid biopsy assays or imaging modalities offer distinct advantages, such as non-invasiveness, real-time monitoring, and comprehensive molecular profiling. These alternatives may provide valuable insights into cancer progression, treatment response, and patient outcomes, often in ways that complement or surpass the capabilities of immuno-oncology assays. As a result, researchers and clinicians may opt for these alternative approaches, particularly in settings where immuno-oncology assays may be limited by sample availability, assay complexity, or cost.

Covid-19 Impact:

Initially, the outbreak led to disruptions in supply chains, laboratory operations, and clinical trials, causing delays in assay development, validation, and commercialization. Restrictions on non-essential medical procedures and laboratory activities also hindered the conduct of immuno-oncology research and the adoption of assay technologies in clinical settings. Furthermore, the redirection of healthcare resources and funding towards COVID-19 response efforts diverted attention and investment away from immuno-oncology research and development. However, as the pandemic progressed, there emerged a heightened recognition of the importance of immunology and infectious disease research, potentially stimulating interest and investment in immuno-oncology assays.

The consumables segment is expected to be the largest during the forecast period

Consumables segment dominated the largest share of the market during the forecast period due to its indispensable role in supporting the operation and scalability of immuno-oncology assays. As the demand for immuno-oncology assays continues to rise, fueled by increasing cancer prevalence and the growing adoption of immunotherapy, the need for consumables also escalates proportionally. Moreover, innovations in assay development often rely on specialized consumables designed to improve assay sensitivity, specificity, and throughput. This creates a continuous demand for consumables within the immuno-oncology assay market.

The flow cytometry segment is expected to have the highest CAGR during the forecast period

Flow Cytometry segment is expected to have the highest CAGR during the projection period due to its versatility and precision in analyzing immune cell populations and their interactions within the tumor microenvironment. This segment allows for the simultaneous measurement of multiple parameters at the single-cell level, providing valuable insights into immune cell phenotypes, activation states, and functional responses. Additionally, flow cytometry enables the assessment of immune checkpoint expression and cytokine production, facilitating the evaluation of immunotherapy efficacy and patient stratification.

Region with largest share:

Asia Pacific region commanded the largest share over the extrapolated period. With a rapidly expanding population, aging demographics, and changing lifestyles, countries across Asia Pacific are experiencing a surge in cancer incidence and mortality rates. Factors such as urbanization, tobacco consumption, pollution, and dietary habits contribute to the rising burden of cancer in the region. As a result, improvements in healthcare infrastructure, access to diagnostic services, and awareness of cancer screening programs are leading to earlier detection and diagnosis of cancer cases in the region thereby enhancing the market growth.

Region with highest CAGR:

Europe region is poised to witness profitable growth throughout the estimation period. The stringent regulatory framework established by European regulatory bodies, such as the European Medicines Agency (EMA) and the European Commission, ensures the safety, efficacy, and quality of immuno-oncology assays used in clinical research and patient care. The European regulatory environment emphasizes transparency, evidence-based decision-making, and ethical considerations, which contribute to building trust and confidence in immuno-oncology assays among stakeholders. As a result, regulatory compliance serves as a catalyst for market growth by facilitating timely market entry, encouraging innovation, and promoting the adoption of immuno-oncology assays for precision medicine and personalized cancer care throughout the European region.

Key players in the market

Some of the key players in Immuno Oncology Assay market include Agilent Technologies, Inc, Bio-Rad Laboratories, Inc, Charles River Laboratories, Inc, F. Hoffmann-La Roche Ltd, Guardant Health, Inc, HTG Molecular Diagnostics, Inc, llumina, Inc, NanoString Technologies, Inc, Novartis International AG, Perkinelmer, Inc, Qiagen Nv, Sartorius AG, Sysmex Corporation and Thermo Fisher Scientific, Inc.

Key Developments:

In January 2024, Thermo Fisher Scientific introduced Gibco(TM) Cell Therapy Systems (CTS(TM)) Cellmation(TM) Software, a new automation solution. It integrates workflows across Thermo Fisher Scientific cell therapy instruments and ensures cGMP compliance for innovators in breakthrough cell therapies.

In March 2023, Mimetas, a company that models human diseases, formed a strategic alliance with Astellas Pharma Inc., a multinational pharmaceutical corporation. The partnership entails using MIMETAS' exhaustive tumor models to assist the next generation of immuno-oncological therapies.

In February 2023, Agilent Technologies, Inc. revealed that their xCELLigence RTCA HT (real-time cell analysis high-throughput) platform is compatible with the BioTek BioSpa 8 Automated Incubator. This combination, developed in response to market demands, enables a higher level of workflow automation and provides novel functionality for developing label-free high-throughput potency assays for the immuno-oncology market and high-throughput viral cytopathic effects (CPE) assays for the vaccine market.

Products Covered:

  • Software
  • Consumables
  • Instruments
  • Other Products

Indications Covered:

  • Bladder Cancer
  • Melanoma Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Lymphoma
  • Other Indications

Technologies Covered:

  • Polymerase Chain Reaction (PCR)
  • Immunoassays
  • Flow Cytometry
  • Next-generation Sequencing (NGS)
  • In Situ Hybridization
  • Other Technologies

Applications Covered:

  • Clinical Diagnostics
  • Research Applications
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Immuno Oncology Assay Market, By Product

  • 5.1 Introduction
  • 5.2 Software
  • 5.3 Consumables
  • 5.4 Instruments
  • 5.5 Other Products

6 Global Immuno Oncology Assay Market, By Indication

  • 6.1 Introduction
  • 6.2 Bladder Cancer
  • 6.3 Melanoma Cancer
  • 6.4 Lung Cancer
  • 6.5 Colorectal Cancer
  • 6.6 Breast Cancer
  • 6.7 Lymphoma
  • 6.8 Other Indications

7 Global Immuno Oncology Assay Market, By Technology

  • 7.1 Introduction
  • 7.2 Polymerase Chain Reaction (PCR)
  • 7.3 Immunoassays
  • 7.4 Flow Cytometry
  • 7.5 Next-generation Sequencing (NGS)
  • 7.6 In Situ Hybridization
  • 7.7 Other Technologies

8 Global Immuno Oncology Assay Market, By Application

  • 8.1 Introduction
  • 8.2 Clinical Diagnostics
  • 8.3 Research Applications
  • 8.4 Other Applications

9 Global Immuno Oncology Assay Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Agilent Technologies, Inc
  • 11.2 Bio-Rad Laboratories, Inc
  • 11.3 Charles River Laboratories, Inc
  • 11.4 F. Hoffmann-La Roche Ltd
  • 11.5 Guardant Health, Inc
  • 11.6 HTG Molecular Diagnostics, Inc
  • 11.7 llumina, Inc
  • 11.8 NanoString Technologies, Inc
  • 11.9 Novartis International AG
  • 11.10 Perkinelmer, Inc
  • 11.11 Qiagen Nv
  • 11.12 Sartorius AG
  • 11.13 Sysmex Corporation
  • 11.14 Thermo Fisher Scientific, Inc

List of Tables

  • Table 1 Global Immuno Oncology Assay Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 4 Global Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 5 Global Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 6 Global Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 7 Global Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 8 Global Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 9 Global Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 10 Global Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 11 Global Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 12 Global Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 13 Global Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 14 Global Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 15 Global Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 16 Global Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 17 Global Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 18 Global Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 19 Global Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 20 Global Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 21 Global Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 22 Global Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 23 Global Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 24 Global Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 25 Global Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 26 North America Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
  • Table 27 North America Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 28 North America Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 29 North America Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 30 North America Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 31 North America Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 32 North America Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 33 North America Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 34 North America Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 35 North America Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 36 North America Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 37 North America Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 38 North America Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 39 North America Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 40 North America Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 41 North America Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 42 North America Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 43 North America Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 44 North America Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 45 North America Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 46 North America Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 47 North America Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 48 North America Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 49 North America Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 50 North America Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 51 Europe Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
  • Table 52 Europe Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 53 Europe Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 54 Europe Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 55 Europe Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 56 Europe Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 57 Europe Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 58 Europe Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 59 Europe Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 60 Europe Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 61 Europe Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 62 Europe Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 63 Europe Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 64 Europe Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 65 Europe Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 66 Europe Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 67 Europe Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 68 Europe Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 69 Europe Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 70 Europe Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 71 Europe Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 72 Europe Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 73 Europe Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 74 Europe Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 75 Europe Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 76 Asia Pacific Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Asia Pacific Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 78 Asia Pacific Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 79 Asia Pacific Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 80 Asia Pacific Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 81 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 82 Asia Pacific Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 83 Asia Pacific Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 84 Asia Pacific Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 85 Asia Pacific Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 86 Asia Pacific Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 87 Asia Pacific Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 88 Asia Pacific Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 89 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 90 Asia Pacific Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 91 Asia Pacific Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 92 Asia Pacific Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 93 Asia Pacific Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 94 Asia Pacific Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 95 Asia Pacific Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 96 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 97 Asia Pacific Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 98 Asia Pacific Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 99 Asia Pacific Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 100 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 101 South America Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 South America Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 103 South America Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 104 South America Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 105 South America Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 106 South America Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 107 South America Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 108 South America Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 109 South America Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 110 South America Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 111 South America Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 112 South America Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 113 South America Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 114 South America Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 115 South America Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 116 South America Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 117 South America Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 118 South America Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 119 South America Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 120 South America Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 121 South America Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 122 South America Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 123 South America Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 124 South America Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 125 South America Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 126 Middle East & Africa Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
  • Table 127 Middle East & Africa Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 128 Middle East & Africa Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 129 Middle East & Africa Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 130 Middle East & Africa Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 131 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 132 Middle East & Africa Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 133 Middle East & Africa Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 134 Middle East & Africa Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 135 Middle East & Africa Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 136 Middle East & Africa Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 137 Middle East & Africa Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 138 Middle East & Africa Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 139 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 140 Middle East & Africa Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 141 Middle East & Africa Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 142 Middle East & Africa Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 143 Middle East & Africa Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 144 Middle East & Africa Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 145 Middle East & Africa Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 146 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 147 Middle East & Africa Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 148 Middle East & Africa Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 149 Middle East & Africa Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 150 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)